Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue SUPPL. A, 1997, Pages 63-72

  Langan, Charles E ^a,b   Cranfield, Roger ^c   Breisch, Sally ^d   Pettit, Ross ^d  

^a Baillieston Health Centre   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c Oak Street Surgery ^*  (United Kingdom)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; GREPAFLOXACIN;

ABDOMINAL PAIN; ADULT; ASTHENIA; BRONCHITIS; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; HAEMOPHILUS INFLUENZAE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORAXELLA CATARRHALIS; MULTICENTER STUDY; NAUSEA; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; VERTIGO; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-INFECTIVE AGENTS; BACTERIA; BACTERIAL INFECTIONS; BRONCHITIS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; FLUOROQUINOLONES; HEMATOLOGIC TESTS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLINS; PIPERAZINES; QUINOLONES; TREATMENT OUTCOME;

EID: 0031475023     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.suppl_1.63     Document Type: Conference Paper

References (15)

1. Doern, G. V. (1995) Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. American Journal of Medicine 99, Suppl. 6B, 3S-7S.
2. Appelbaum, P.C. (1992). Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clinical Infectious Diseases 15, 77-83.
3. Doern, G. V., Brueggemann, A., Holley, H. P. & Rauch, A. M. (1996). Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrobial Agents and Chemotherapy 40, 1208-13.
4. Linares, J., Pallares, R., Alonso, T., Perez, J. L., Ayates, J., Gudiol, F. et al. (1992). Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain 1979-1990. Clinical Infectious Diseases 15, 99-105.
5. Gargallo., D., Moros, M., Coll, R., Esteve, M., Pares, J., Xicota, M. A. et al. (1988). Activity of E-3846: a new fluoroquinolone, in vitro and in experimental cystitis and pyelonephritis in rats. Antimicrobial Agents and Chemotherapy 32, 636-41.
6. Hoban, D. J. (1989). Comparative in vitro activity of quinolones. Clinical and Investigative Medicine 12, 10-8.
7. Spangler, S. K., Jacobs, M. R., Pankuch, G. A. & Appelbaum, P. C. (1993). Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, RO 23-9424 and RP 67829. Journal of Antimicrobial Chemotherapy 31, 273-80.
8. Fuchs, P. C., Barry, A. L. & Brown, S. D. (1996). Tentative interpretative criteria for testing susceptibility of Streptococcus pneumoniae to eight fluoroquinolones. Diagnostic Microbiology and Infectious Disease 26, 23-7.
9. Imada, T., Miyazaki, S., Nishida, M., Yamaguchi, K. & Goto, S. (1992). In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrobial Agents and Chemotherapy 36, 573-9.
10. Neu, H. C., Fang, W., Gu, J. W. & Chin, N. X. (1992). In vitro activity of OPC-17116. Antimicrobial Agents and Chemotherapy 36, 1310-5.
11. Sader, H. S., Erwin, M. E. & Jones, R. N. (1992). In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones. European Journal of Clinical Microbiology and Infectious Diseases 11, 372-81.
12. Wise, R., Andrews, J. M. & Brenwald, N. (1993). The in vitro activity of OPC-17116, a new 5-methyl substituted quinolone. Journal of Antimicrobial Chemotherapy 31, 497-504.
13. Child, J., Andrews, J. M. & Wise, R. (1995). Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. Antimicrobial Agents and Chemotherapy 39, 513-5.
14. Greenberg, R. N. (1984). Overview of patient compliance with medication dosing: a literature review. Clinical Therapeutics 6, 592-9.
15. Eisen S. A., Miller, D. K., Woodward, R. S., Spitznagel, E. & Przybeck, T. R. (1990). The effect of prescribed daily dose frequency on patient medication compliance. Archives of Internal Medicine 150, 1881-4.